A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma.
Two hundred sixty-seven patients with advanced epithelial ovarian carcinoma were randomized to cis-platinum and cyclophosphamide versus cis-platinum, cyclophosphamide, and doxorubicin. Complete pathological response, evaluated at second-look laparotomy and survival, showed no differences between the two treatment groups. Recurrence-free survival after negative second look was 61% at 24 months.
Bertelsen
K
K
Danish Ovarian Cancer Group, Department of Oncology, University Hospital, Odense, Denmark.
Jakobsen
A
A
Andersen
J E
JE
Ahrons
S
S
Pedersen
P H
PH
Kiaer
H
H
Arffmann
E
E
Bichel
P
P
Boestofte
E
E
Strøyer
I
I
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000401:mortality; D002945:Cisplatin / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality; D011897:Random Allocation
D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin